All In Biotech

Investigational drug · Phase 3

BGM0504 Administered

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM).

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

15

Any phase or sponsor naming "BGM0504 Administered"

First trial start

2025

Jan 3, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BGM0504 Administered", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 2 Diabetes Mellitus (T2DM)

Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "BGM0504 Administered" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Type 2 Diabetes Mellitus (T2DM)

  • BofanglutideGZR18, BofanglutidaPhase 311 trials

    Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult

  • MWN109 1Phase 36 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • MWN109 2Phase 36 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • MWN109 3Phase 35 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • AD-233APhase 31 trial

    Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)

  • AD-233BPhase 31 trial

    Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)

  • AD-233CPhase 31 trial

    Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)

  • AD-233DPhase 31 trial

    Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.